FIELD: pharmacology.
SUBSTANCE: group of inventions refers to a drug for intravenous administration or a water-soluble solid preparation containing 7-dimethylaminotetracycline and a magnesium cation with a molar ratio of the magnesium cation to tetracycline of more than 3:1, as well as to methods for their preparation, kits for preparation of an aqueous solution for intravenous administration and drugs application for bacterial infection treatment or prevention.
EFFECT: group of inventions allows to obtain a drug containing 7-dimethylaminotetracycline and a magnesium cation as a solution with a possibility of its application for injections.
60 cl, 7 dwg, 36 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRACYCLINE COMPLEXES WITH SUSTAINABLE ACTIVITY | 2019 |
|
RU2806036C2 |
| USING LEVOFLOXACIN IN AEROSOL FORM FOR TREATING MUCOVISCIDOSIS | 2010 |
|
RU2563809C2 |
| AEROSOL FLUOROCHINOLONES AND THEIR APPLICATIONS | 2006 |
|
RU2428986C2 |
| AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF | 2006 |
|
RU2603638C2 |
| IMPROVED METHOD OF PRODUCING INTERMEDIATE COMPOUND OF TIGECYCLINE AND METHOD OF PRODUCING TIGECYCLINE THEREFROM | 2021 |
|
RU2819296C1 |
| TIGECYCLINE COMPOSITION AND METHODS FOR PREPARING | 2006 |
|
RU2428190C2 |
| AQUEOUS COMPOSITIONS CONTAINING ARBEKACINE | 2012 |
|
RU2604767C2 |
| STANDARDISED SENSITIVITY TESTS FOR AEROBIC PATHOGENS | 2004 |
|
RU2354705C2 |
| METHOD | 2012 |
|
RU2621681C2 |
| PHARMACEUTICAL COMPOSITION OF KAPPA OPIOID RECEPTOR AGONIST | 2019 |
|
RU2768482C1 |
